Date published: 2026-2-22

1-800-457-3801

SCBT Portrait Logo
Seach Input

1810037I17Rik Activators

1810037I17Rik Activators are a specialized group of chemical compounds that act on various signaling pathways to enhance the activity of 1810037I17Rik. Forskolin, by raising cAMP levels, indirectly augments the activity of 1810037I17Rik through the activation of PKA, which may phosphorylate and thereby activate 1810037I17Rik itself or associated regulatory proteins. In parallel, IBMX increases cAMP by inhibiting its degradation, which also indirectly promotes 1810037I17Rik activity. Additionally, Epigallocatechin gallate and Genistein serve as kinase inhibitors, potentially relieving 1810037I17Rik from inhibitory phosphorylation or modulating kinase-regulated signaling pathways that interact with 1810037I17Rik. PMA, through activation of PKC, and U0126, by inhibiting MEK1/2, offer additional pathways to enhance 1810037I17Rik activity, either through direct phosphorylation or by altering the phosphorylation state of proteins within the MAPK pathway. This particular gene is relevant to the function and regulation of certain cellular processes in mice.

During this screening, the 1810037I17Rik gene promoter is typically linked to a reporter gene, such as luciferase, to create a reporter assay system. This system is designed to emit a measurable light signal when the promoter is activated. Compounds that trigger a significant increase in luminescence are indicative of interaction with the promoter, resulting in gene activation. These compounds are then considered candidates for 1810037I17Rik Activators and are subjected to further validation to confirm their activity. Quantitative PCR (qPCR) is used to measure the mRNA levels of the 1810037I17Rik gene after the application of the compounds, providing a direct assessment of gene expression. This technique quantifies the expression levels to confirm that the mRNA is being produced at elevated levels upon compound interaction. Western blot analysis is subsequently conducted to determine if the increase in mRNA is matched by an increase in the production of the corresponding protein.

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

IBMX

28822-58-4sc-201188
sc-201188B
sc-201188A
200 mg
500 mg
1 g
$260.00
$350.00
$500.00
34
(1)

IBMX is a non-selective phosphodiesterase inhibitor, leading to increased cAMP by preventing its breakdown. This accumulation can indirectly enhance 1810037I17Rik activity if 1810037I17Rik function is modulated by cAMP-dependent signaling pathways.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

This polyphenol inhibits several protein kinases, potentially reducing negative regulatory phosphorylation events, which could lead to enhanced activity of 1810037I17Rik if it is regulated by such kinases.

PMA

16561-29-8sc-3576
sc-3576A
sc-3576B
sc-3576C
sc-3576D
1 mg
5 mg
10 mg
25 mg
100 mg
$41.00
$132.00
$214.00
$500.00
$948.00
119
(6)

PMA activates protein kinase C (PKC), which may enhance the activity of 1810037I17Rik by phosphorylating it directly or phosphorylating associated regulatory proteins that influence 1810037I17Rik's functional state.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$123.00
$400.00
148
(1)

A PI3K inhibitor that could lead to increased activity of 1810037I17Rik by altering signaling pathways that negatively regulate 1810037I17Rik through PI3K-dependent pathways.

D-erythro-Sphingosine-1-phosphate

26993-30-6sc-201383
sc-201383D
sc-201383A
sc-201383B
sc-201383C
1 mg
2 mg
5 mg
10 mg
25 mg
$165.00
$322.00
$570.00
$907.00
$1727.00
7
(1)

This lipid signaling molecule could enhance 1810037I17Rik activity by activating sphingosine-1-phosphate receptors that may be part of signaling cascades interacting with 1810037I17Rik.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$136.00
$446.00
114
(2)

Thapsigargin raises intracellular calcium levels by inhibiting the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA). Increased calcium signaling might enhance 1810037I17Rik activity if calcium-dependent signaling pathways modulate it.

A23187

52665-69-7sc-3591
sc-3591B
sc-3591A
sc-3591C
1 mg
5 mg
10 mg
25 mg
$55.00
$131.00
$203.00
$317.00
23
(1)

A23187 is a calcium ionophore that increases intracellular calcium concentration, which could indirectly enhance the activity of 1810037I17Rik through activation of calcium-dependent signaling pathways.

Staurosporine

62996-74-1sc-3510
sc-3510A
sc-3510B
100 µg
1 mg
5 mg
$82.00
$153.00
$396.00
113
(4)

As a broad-spectrum kinase inhibitor, staurosporine might non-selectively enhance 1810037I17Rik activity by inhibiting kinases that negatively regulate 1810037I17Rik or its associated signaling pathways.

Genistein

446-72-0sc-3515
sc-3515A
sc-3515B
sc-3515C
sc-3515D
sc-3515E
sc-3515F
100 mg
500 mg
1 g
5 g
10 g
25 g
100 g
$45.00
$164.00
$200.00
$402.00
$575.00
$981.00
$2031.00
46
(1)

Genistein is a tyrosine kinase inhibitor that may enhance 1810037I17Rik activity by reducing competitive phosphorylation events or by modulating signaling pathways that intersect with tyrosine kinase-regulated processes involving 1810037I17Rik.